European Journal of Cancer
Volume 42, Issue 15 , Pages 2499-2503 , October 2006

1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment

  • Mathilde C.M. Kouwenhoven

      Affiliations

    • Department of Neuro-Oncology, Daniel den Hoed Oncology Center, P.O. Box 5201, 3008AE Rotterdam, The Netherlands
    • ,
  • Johan M. Kros

      Affiliations

    • Department of Pathology, ErasmusMC Rotterdam, The Netherlands
    • ,
  • Pim J. French

      Affiliations

    • Department of Neuro-Oncology, Daniel den Hoed Oncology Center, P.O. Box 5201, 3008AE Rotterdam, The Netherlands
    • ,
  • Elize M. Biemond-ter Stege

      Affiliations

    • Department of Neuro-Oncology, Daniel den Hoed Oncology Center, P.O. Box 5201, 3008AE Rotterdam, The Netherlands
    • ,
  • Wilfried J. Graveland

      Affiliations

    • Department of Pathology, ErasmusMC Rotterdam, The Netherlands
    • Department of Medical Statistics, Daniel den Hoed Oncology Center, Rotterdam, The Netherlands
    • ,
  • Martin J.B. Taphoorn

      Affiliations

    • Department of Neurology, MC Haaglanden-Westeinde Hospital, The Hague, The Netherlands
    • ,
  • Alba A. Brandes

      Affiliations

    • Medical Oncology Department, Neuroncology Unit, Azienda Ospedale-Università-Istituto Oncologico Veneto, Padova, Italy
    • ,
  • Martin J. van den Bent

      Affiliations

    • Department of Neuro-Oncology, Daniel den Hoed Oncology Center, P.O. Box 5201, 3008AE Rotterdam, The Netherlands
    • Corresponding Author InformationCorresponding author: Tel.: +31 10 4391415; fax: +31 10 4391031.

Received 25 April 2006 ,Accepted 2 May 2006.

References 

  1. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12(10):2013–2021
  2. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumours: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol. 2003;21(13):2525–2528
  3. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol. 2003;14(12):1715–1721
  4. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol. 2001;19(9):2449–2455
  5. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90(19):1473–1479
  6. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol. 2003;61(3):267–273
  7. Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas. Neurology. 2004;63(5):904–906
  8. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. 2004;22(15):3133–3138
  9. van den Bent MJ, Looijenga LH, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumours are correlated with clinical features. Cancer. 2003;97(5):1276–1284
  10. Soffietti R. Chemotherapy of anaplastic oligodendroglial tumours. Exp Opin Pharmacother. 2004;5(2):295–306
  11. van den Bent MJ. New perspectives for the diagnosis and treatment of oligodendroglioma. Exp Rev Anticancer Ther. 2001;1(3):348–356
  12. Brandes AA, Ermani M, Basso U, et al. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. Ann Oncol. 2001;12(2):255–257
  13. van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol. 2003;14(4):599–602
  14. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–1280
  15. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18(3):636–645
  16. Stock C, Ambros IM, Mann G, Gadner H, Amann G, Ambros PF. Detection of Ip36 deletions in paraffin sections of neuroblastoma tissues. Genes Chromosomes Cancer. 1993;6(1):1–9
  17. Perry A. Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol. 2001;8(4):183–199
  18. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997;79(7):1381–1393
  19. Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG. Trends in incidence of primary brain tumours in the United States, 1985–1994. Neurooncol. 2001;3(3):141–151
  20. Ino Y, Zlatescu MC, Sasaki H, et al. Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg. 2000;92(6):983–990

PII: S0959-8049(06)00521-1

doi: 10.1016/j.ejca.2006.05.021

European Journal of Cancer
Volume 42, Issue 15 , Pages 2499-2503 , October 2006

Article Tools

* Image Usage & Resolution